Physician profile
Ronit Friedman
NPI 1518047075
$1,989.12
in general payments reported to CMS, 2019-2025
30 companies · $995 in 2025
The $995 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2023: $125 · 2024: $754 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,676 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,676.40 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $352.85 | 2024-2025 | Evenity, Prolia, Prolia |
| Astellas Pharma US INC | $287.23 | 2023-2025 | Veozah |
| Abbvie INC. | $148.05 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $132.77 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $105.96 | 2023-2025 | |
| Janssen Biotech, INC. | $101.73 | 2024-2025 | Tremfya |
| Biogen, INC. | $100.00 | 2024 | Zurzuvae |
| Mannkind Corporation | $89.19 | 2024-2025 | |
| Radius Health, INC. | $88.77 | 2024-2025 | Tymlos |
| Lilly USA, LLC | $75.82 | 2025 | Zepbound |
| Exact Sciences Corporation | $61.63 | 2025 | Cologuard Collection Kit |
| Ucb, INC. | $53.15 | 2025 | Bimzelx |
| Ascendis Pharma Endocrinology INC | $36.81 | 2025 | Yorvipath |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.98 | 2024 | Xifaxan, Trulance |
| Ibsa Pharma INC. | $32.47 | 2024 | Licart, Tirosint |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $30.45 | 2024 | |
| Pfizer INC. | $28.92 | 2024 | |
| Mayne Pharma Commercial LLC | $27.16 | 2025 | |
| Aurinia Pharma U.S., INC. | $21.10 | 2025 | Lupkynis |
| Sun Pharmaceutical Industries INC. | $18.25 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $18.17 | 2024 | Zoryve |
| Corcept Therapeutics | $17.11 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $16.84 | 2023 | Trelegy Ellipta |
| Recordati_rare_diseases_inc. | $16.71 | 2024 | Isturisa, Signifor Lar |
| Kyowa Kirin, INC. | $16.53 | 2024 | Crysvita |
| Lundbeck LLC | $16.35 | 2024 | Vyepti |
| Ani Pharmaceuticals, INC. | $16.08 | 2024 | Purified Cortrophin Gel |
| Kiniksa Pharmaceuticals International, Plc | $16.07 | 2024 | Arcalyst |
| Invivyd INC | $15.71 | 2025 | Pemgarda |
| Idorsia Pharmaceuticals US INC | $14.26 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronit Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.